Everolimus Eluting Stents Versus Coronary Artery Bypass Graft Surgery for Patients With Diabetes Mellitus and Multivessel Disease

• DOI: 10.1161/circinterventions.115.002626
• Publication Date: 2015-07-09T02:55:17Z
• Authors: Sripal Bangalore; Yu Guo; Zaza Samadashvili; Saul Blecker; Jinfeng Xu; Edward L. Hannan
• Keywords: Stroke; Bypass surgery

In patients with diabetes mellitus and multivessel disease, coronary artery bypass graft surgery percutaneous intervention are treatment options. However, there is paucity of data comparing against newer generation stents.Patients included in the New York State registries who had underwent isolated or everolimus eluting stent (EES) for disease were included. Propensity score matching was used to assemble a cohort similar baseline characteristics. The primary outcome all-cause mortality. Secondary outcomes myocardial infarction (MI), stroke, repeat revascularization. Short-term (within 30 days) long-term evaluated. Among 16,089 8096 propensity scores At short-term, EES associated lower risk death (hazard ratio [HR] =0.58; 95% confidence interval [CI], 0.34-0.98; P=0.04) stroke (HR=0.14; CI, 0.06-0.30; P<0.0001) but higher MI (HR=2.44; 1.13-5.31; P=0.02). long-term, (425 [10.50%] versus 414 [10.23%] events; HR=1.12; 0.96-1.30; P=0.16), (118 [2.92%] 157 [3.88%] HR=0.76; 0.58-0.99; (260 [6.42%] 166 [4.10%] HR=1.64; 1.32-2.04; revascularization (889 [21.96%] 421 [10.40%] HR=2.42; 2.12-2.76; P<0.0001). not seen subgroup complete (HR=1.37; 0.76-2.47; P=0.30).In upfront when compared surgery. at death, (in those incomplete revascularization), stroke.